Bortezomib

Overview

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome ( K i =0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis , and inhibits NF-κB . Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > PROTAC | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > TREM receptor | Products > Signaling Pathways > Ligands for Target Protein for PROTAC | Products > Signaling Pathways > Proteasome | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-10227
• CAS No.: 179324-69-7
• Molecular Formula: C19H25BN4O4
• Molecular Weight: 384.24
• Purity: 99.80%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution
• Availability: In-stock

Source

Original product source